NO20005621L - Nye medikamentkombinasjoner - Google Patents

Nye medikamentkombinasjoner

Info

Publication number
NO20005621L
NO20005621L NO20005621A NO20005621A NO20005621L NO 20005621 L NO20005621 L NO 20005621L NO 20005621 A NO20005621 A NO 20005621A NO 20005621 A NO20005621 A NO 20005621A NO 20005621 L NO20005621 L NO 20005621L
Authority
NO
Norway
Prior art keywords
disorders
new drug
drug combinations
disorder
anxiety
Prior art date
Application number
NO20005621A
Other languages
English (en)
Other versions
NO20005621D0 (no
Inventor
Duncan Paul Taylor
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20005621L publication Critical patent/NO20005621L/no
Publication of NO20005621D0 publication Critical patent/NO20005621D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ny kombinasjonsbehandling av selektive, noradrenalinreopptaksinhibitorer (NARI) og spesielt reboxetin og pindolol, for å frembringe rask lindring for pasienter som lider av depresjon, generell angst, "attention deficit hyperactivity disorder (ADHD), angstforstyrrelser slik som "obsessive compulsive disorders " (OCD), paniske forstyrrelser (PD), sosiale fobier (SD) og liknende.
NO20005621A 1998-05-08 2000-11-07 Nye medikamentkombinasjoner NO20005621D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (2)

Publication Number Publication Date
NO20005621L true NO20005621L (no) 2000-11-07
NO20005621D0 NO20005621D0 (no) 2000-11-07

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005621A NO20005621D0 (no) 1998-05-08 2000-11-07 Nye medikamentkombinasjoner

Country Status (22)

Country Link
EP (1) EP1075264B1 (no)
JP (1) JP2002514601A (no)
KR (1) KR20010052319A (no)
CN (1) CN1300217A (no)
AT (1) ATE283694T1 (no)
AU (1) AU764579B2 (no)
BR (1) BR9909559A (no)
CA (1) CA2326105A1 (no)
DE (1) DE69922367T2 (no)
EA (1) EA003469B1 (no)
ES (1) ES2232128T3 (no)
HU (1) HUP0101341A3 (no)
IL (1) IL139211A0 (no)
NO (1) NO20005621D0 (no)
NZ (1) NZ508035A (no)
PL (1) PL345351A1 (no)
PT (1) PT1075264E (no)
SI (1) SI1075264T1 (no)
SK (1) SK14502000A3 (no)
TR (1) TR200003262T2 (no)
WO (1) WO1999058130A1 (no)
ZA (1) ZA200005301B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1459751B1 (en) * 1999-07-01 2005-09-14 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating migraine headaches
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US20120077818A1 (en) * 2009-05-13 2012-03-29 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response

Also Published As

Publication number Publication date
SI1075264T1 (en) 2005-06-30
BR9909559A (pt) 2000-12-19
SK14502000A3 (sk) 2001-05-10
NO20005621D0 (no) 2000-11-07
AU764579B2 (en) 2003-08-21
ZA200005301B (en) 2001-10-01
PT1075264E (pt) 2005-01-31
EA200001162A1 (ru) 2001-04-23
EP1075264B1 (en) 2004-12-01
WO1999058130A1 (en) 1999-11-18
DE69922367D1 (de) 2005-01-05
CN1300217A (zh) 2001-06-20
KR20010052319A (ko) 2001-06-25
DE69922367T2 (de) 2005-12-22
JP2002514601A (ja) 2002-05-21
CA2326105A1 (en) 1999-11-18
AU3546099A (en) 1999-11-29
ES2232128T3 (es) 2005-05-16
TR200003262T2 (tr) 2001-03-21
PL345351A1 (en) 2001-12-17
NZ508035A (en) 2004-02-27
ATE283694T1 (de) 2004-12-15
HUP0101341A3 (en) 2006-07-28
EA003469B1 (ru) 2003-06-26
IL139211A0 (en) 2001-11-25
EP1075264A1 (en) 2001-02-14
HUP0101341A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
Shulman et al. Current place of monoamine oxidase inhibitors in the treatment of depression
Brunello et al. Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment
NO20100333L (no) Behandling av nevrotiske forstyrrelser
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
PT1066036E (pt) Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono
CL2008002866A1 (es) Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno adictivo, trastorno mental, trastorno de deficit atencional, trastorno bipolar, obesidad, trastorno de panico, trastorno psicotico, sindrome de inhibicion selectiva de la recaptacion de serotonina, entre otras (sol. div. 1765-00).
DK1253918T3 (da) Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD))
NO20052420L (no) Farmakologisk behandling av sovnapn±.
DE60234246D1 (de) Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
DK1626720T3 (da) 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
NO20005621D0 (no) Nye medikamentkombinasjoner
WO2002040006A3 (en) Treatment of anxiety disorders
UA84692C2 (ru) Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения
DK1071418T3 (da) Nye behandlinger til nervelidelser
BR0316475A (pt) Combinação sinergìstica que compreende roflumilast e (r,r)-formoterol
Pierò et al. An open, non‐randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ITRM20010218A1 (it) Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
Casacchia et al. Brain serotonin and the mechanism of action of selective serotonin re-uptake inhibitors (SSRI)
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
SE9803732D0 (sv) Nicotine treatment for obsessive compulsive disorder
NO20061427L (no) Kombinasjonen av en serotonin-reoppttaksinhibitor og amoxapin
WO2024259343A3 (en) New formulations for mental disorders or mental enhancement
SSRI SSRIs for premenstrual dysphoric disorder

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application